生殖系变异影响慢性肝病的进展通过不同的途径
Marijana Vujkovic1,2,3, David E Kaplan1,4, Jonas Ghouse5,6,7
1Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
medRxiv : the preprint server for health sciences
|September 26, 2025
概括
这项研究确定了与肝硬化和肝癌 (HCC) 相关的新遗传位置,揭示了预测慢性肝病 (CLD) 患者疾病进展和治疗反应的遗传风险得分.
科学领域:
- 遗传学 是一个遗传学.
- 肝病学 肝病学是一种肝病学.
- 基因组学就是基因组学.
背景情况:
- 慢性肝病 (CLD) 可以导致肝硬化和肝细胞癌 (HCC).
- 了解影响CLD进展的遗传因素对于开发向疗法至关重要.
研究的目的:
- 通过大规模的全基因组关联研究 (GWAS) 来确定与肝硬化和HCC相关的遗传位置.
- 调查基因变异在CLD患者疾病进展和治疗反应中的作用.
主要方法:
- 对肝硬化和HCC进行了多祖先GWAS,包括对全基因组测序数据的基因负担分析.
- 利用大型队列进行发现和复制,分析遗传风险得分和治疗相互作用.
主要成果:
- 鉴定了27个肝硬化位点 (10个新型) 和11个HCC (3个新型),其中包括FGF21,RPTOR,IFNL3/4,GSTA5,APOB和ATP9B等特定基因.
- 一个高的肝硬化遗传风险得分显著增加了CLD进展到肝硬化和肝硬化到HCC的风险.
- 遗传变异改变了慢性型肝炎患者的治疗反应.
结论:
- 揭示了对肝硬化和HCC.病变的新型遗传洞察力.
- 证明了基因风险评分在预测CLD进展方面的临床实用性.
- 强调了个性化医疗方法在治疗CLD及其并发症方面的潜力.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
214
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214
Cell Specific Gene Expression
16.3K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.3K
Diseases of the Liver and Gallbladder
1.9K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.9K
Hepatic Drug Excretion: Influencing Factors
526
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
526
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
256
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
256


